New FDA-approved biologics have changed the treatment landscape for neuromyelitis optica spectrum disorder (NMOSD), a devastating autoimmune disorder. Monoclonal antibodies like ravulizumab have shown promise in preventing recurrence of optic neuritis and myelitis. Eculizumab, satralizumab, and inebilizumab have also been approved for NMOSD treatment, with eculizumab demonstrating a significant reduction in relapse risk. The challenge with these biologics is their high cost and frequent dosing requirements. However, the newer drug ravulizumab may address these issues with its less frequent dosing schedule. Research and optimization of these new treatments offer hope for patients with NMOSD.
Source link
FDA approves Ultomiris for neuromyelitis optica spectrum disorder
